Commitments and Contingencies (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | |||||
|---|---|---|---|---|---|---|---|
Aug. 05, 2020 |
Aug. 03, 2020 |
Jun. 21, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
Sep. 30, 2020 |
Sep. 30, 2019 |
|
| Litigation settlement expense | $ 75,000 | ||||||
| Chube Workx [Member] | |||||||
| Stock issued during the period | 2,510,000 | ||||||
| Novotek Therapeutics Inc., and NovoTek Pharmaceuticals Limited [Member] | |||||||
| Loss contingency, damages sought, value | $ 1,551,562 | ||||||
| Lump sum payment | $ 1,350,000 | ||||||
| Settlement Agreement and General Release [Member] | |||||||
| Number of shares issued | $ 300,000 | ||||||
| Stock issued during the period | 500,000 | ||||||
| Litigation settlement expense | $ 2,810,000 | $ 2,810,000 | |||||
| X | ||||||||||
- Definition Lump sum payment. No definition available.
|
| X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|
| X | ||||||||||
- Definition The value (monetary amount) of the award the plaintiff seeks in the legal matter. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|